Why the study?
To determine threshold cytomegalovirus infectious rates and treatment effectiveness required to make universal prenatal screening cost-effective.
Does universal prenatal serum screening for CMV improve cost-effectiveness compared to routine risk-based screening in pregnant women?
Does universal prenatal serum screening for CMV improve cost-effectiveness compared to routine risk-based screening in pregnant women?
Universal maternal screening for CMV is cost-effective if the incidence of primary CMV in pregnancy is greater than 0.89% and behavioral intervention effectiveness is greater than 75%.
Answers are grounded in this paper and cite their sources.
Universal CMV screening not cost-effective at base rates/efficacy; leaves open thresholds for adoption pending better HIG data.
OBJECTIVE: To determine threshold cytomegalovirus (CMV) infectious rates and treatment effectiveness to make universal prenatal CMV screening cost-effective. STUDY DESIGN: Decision analysis comparing cost-effectiveness of two strategies for the prevention and treatment of congenital CMV: universal prenatal serum screening and routine, risk-based screening. The base case assumptions were a probability of primary CMV of 1% in seronegative women, hyperimmune globulin (HIG) effectiveness of 0%, and behavioral intervention effectiveness of 85%. Screen-positive women received monthly HIG and screen-negative women received behavioral counseling to decrease CMV seroconversion. The primary outcome was the cost per maternal quality-adjusted life year (QALY) gained with a willingness to pay of $100,000 per QALY. RESULTS: In the base case, universal screening is cost-effective, costing $84,773 per maternal QALY gained. In sensitivity analyses, universal screening is cost-effective only at a primary CMV incidence of more than 0.89% and behavioral intervention effectiveness of more than 75%. If HIG is 30% effective, primary CMV incidence can be 0.82% for universal screening to be cost-effective. CONCLUSION: The cost-effectiveness of universal maternal screening for CMV is highly dependent on the incidence of primary CMV in pregnancy. If efficacious, HIG and behavioral counseling allow universal screening to be cost-effective at lower primary CMV rates.
No takes yet. Share an insight, caveat, or question.
Albright et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: